• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Fosun Pharma

Graphic of two hands shaking under a red and purple light
Biotech

Fosun pays $32M to join Lilly and Novartis in psoriasis market

A Fosun Pharma subsidiary has paid Junshi Biosciences $32 million for Chinese rights to a near-approval autoimmune disease drug candidate.
Nick Paul Taylor Jul 2, 2026 8:30am
Fosun
Favicon Fierce Pharma

Fosun Pharma plots global push, fueled by Alzheimer’s deals

Jun 25, 2026 7:00pm
drawing of magnifying glass on a brain

Fosun pays $60M for option on AriBio’s phase 3 Alzheimer’s asset

May 13, 2026 9:15am
human brain abstract art

Insilico agrees to $66M deal to split rights for NLRP3 inhibitor

Jan 21, 2026 7:05am
Space shuttle takes off on background of blue sky

VC Aditum launches new biotech for foray with Fosun

Dec 19, 2025 11:25am
Hiking gear with a forest in the background

Expedition resupplies for ph. 2 COPD voyage with $165M series A

Oct 9, 2025 9:50am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings